Project Grant R01AI187430
Award Date 8/15/25
Completion Date 7/31/30
Dollars Obligated $344K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
- This federal Project Grant award of $3,248,576.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the cross-protective efficacy of the recently FDA-approved IXCHIQ live attenuated chikungunya virus vaccine against other alphavirus species. The key objectives are to: 1) Determine the ability of IXCHIQ-induced immunity to protect against heterologous alphavirus...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $281,786 to L2 Diagnostics LLC for the development of a safe and effective viral vector-based vaccine to induce both humoral and cellular immune protection against Powassan virus. The goal is to leverage the Modified Vaccinia Ankara vector platform to stimulate robust antibody and T cell responses that...
- This federal Project Grant award of $883,864 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a thermostable measles fusion (F) glycoprotein vaccine strategy. The key objectives are to engineer a thermostable measles F protein immunogen and evaluate the protective immune responses it elicits, with the goal of creating a vaccine that is safe and effective for...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to develop broadly inhibitory alphavirus antibody therapies. The $1,687,240 award, with a performance period from June 6, 2025 to May 31, 2030, will fund efforts to engineer Fc mutations into existing broadly protective antibodies and perform viral escape studies to define mechanisms of...
- This $452,769 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the impact of the BDGR-49 compound on preventing long-term neurological sequelae caused by Venezuelan equine encephalitis virus (VEEV) infection. The research, conducted by Virginia Polytechnic Institute & State University, aims to determine if BDGR-49 can reduce VEEV replication...
- This federal Project Grant award of $294,583, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel cost-effective multispecific antibody therapeutic product for dengue by Mapp Biopharmaceutical, Inc. The goal is to create a therapeutic that combines the efficacy of two broadly neutralizing antibodies into a single half-life extended molecule, enabling higher...
- This $1,486,800 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate the unexpected role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) for vaccine development against Herpes Simplex Virus (HSV). The research involves engineering a novel single-cycle HSV vaccine strain, isolating potent...
- This federal Project Grant award of $708,202, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research to identify targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The award to Brown University will: 1) conduct a case-control study in Kenya to identify infants and children with severe malaria and matched controls, 2)...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $207,262 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in Saint Louis to develop an mRNA vaccine against Bourbon virus, an emerging tick-borne pathogen. The primary objective is to evaluate the efficacy of the mRNA vaccine in a mouse model and determine its mechanism of action. A secondary objective is to test different viral antigens and...
- This federal Project Grant award of $299,954 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of L2 Diagnostics LLC's novel malaria vaccine candidate called PFAG. The project aims to (i) optimize the PFAG vaccine construct and (ii) conduct efficacy testing to confirm the optimal design. PFAG is a multivalent peptide vaccine composed of synthetic peptides representing...